HMMJ.TO - Horizons Marijuana Life Sciences ETF

Toronto - Toronto Delayed Price. Currency in CAD
16.40
0.00 (0.00%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close16.40
Open16.48
Bid16.35 x 0
Ask16.41 x 0
Day's Range16.12 - 16.77
52 Week Range8.21 - 25.56
Volume309,564
Avg. Volume674,429
Net Assets697.44M
NAV17.99
PE Ratio (TTM)N/A
YieldN/A
YTD Return-5.18%
Beta (3y)N/A
Expense Ratio (net)0.00%
Inception Date2017-04-04
  • Is the US Warming Up to Cannabis Legalization?
    Market Realist2 days ago

    Is the US Warming Up to Cannabis Legalization?

    On April 20, the cannabis sector saw more positive news came from the US, as Senator Chuck Schumer discussed intentions to introduce legislation decriminalizing cannabis, which currently is a Schedule 1 drug in the US.

  • Cannabis Sector Closes Positively in the Week Ended April 13
    Market Realist9 days ago

    Cannabis Sector Closes Positively in the Week Ended April 13

    Last week (ended April 13), overall market sentiment was positive, with the S&P 500 rising 2% and the TSX 30 gaining 44 basis points. The cannabis sector ended the week positively, breaking its losing streak. 

  • MarketWatch12 days ago

    John Boehner is joining a marijuana company

    The legalized-marijuana movement will likely welcome the news Wednesday that two prominent former politicians are joining a cannabis company.

  • Why Hydropothecary Stock Rose 13% Yesterday
    Market Realist13 days ago

    Why Hydropothecary Stock Rose 13% Yesterday

    On April 11, Hydropothecary (HYYDF) stock surged 13.2% after it became the SAQ’s (Société des alcools du Québec) preferred non-medical cannabis supplier once non-medical cannabis becomes legal in Canada. The company’s press release stated that the agreement term extends to the first five years following legalization and has an option to extend for another year.

  • CNW Group14 days ago

    Horizons ETFs Wins Three Gramercy Awards for Marketing Excellence

    Horizons ETFs Wins Three Gramercy Awards for Marketing Excellence

  • CNW Group15 days ago

    Horizons Marijuana Life Sciences Index ETF Celebrates Its One-Year Anniversary with the Best 12-Month ETF Performance in Canada

    Horizons Marijuana Life Sciences Index ETF Celebrates Its One-Year Anniversary with the Best 12-Month ETF Performance in Canada

  • Cannabis Sector Roundup for the Week Ended April 6
    Market Realist16 days ago

    Cannabis Sector Roundup for the Week Ended April 6

    Last week, the S&P 500 Index (SPY) ended up with a fall of 1.4%, and the TSX 300 Composite Index ended the week with a fall of nearly 1%.

  • Cannabis Stocks Continue Their Free Fall
    Market Realist20 days ago

    Cannabis Stocks Continue Their Free Fall

    As of April 4, markets continued to weigh down on the cannabis sector for the third straight day in a row. The Horizons Marijuana Life Science ETF (HMMJ) ended almost 80 basis points lower than its previous day’s close. This ETF is down almost 27%, indicating weakness in the cannabis sector YTD (year-to-date).

  • What Happened in the Cannabis Sector Last Week?
    Market Realist23 days ago

    What Happened in the Cannabis Sector Last Week?

    What Happened in the Cannabis Sector Last Week?Cannabis sector

  • Hydropothecary’s Operating Expense Swells in Fiscal 2Q18
    Market Realist23 days ago

    Hydropothecary’s Operating Expense Swells in Fiscal 2Q18

    Hydropothecary (HYYDF) reported a fall during fiscal 2Q18 due to a big increase in its operating expense YoY (year-over-year). The company’s operating expense rose from 1.7 million Canadian dollars in fiscal 2Q17 to 5.5 million Canadian dollars in fiscal 2Q18. Standardizing this as a percentage of its sales, Hydropothecary’s operating expenses rose from 1.9x its sales in fiscal 2Q17 to 4.6x its sales in fiscal 2Q18.

  • Key Takeaways from Hydropothecary’s Fiscal 2Q18 Earnings
    Market Realist26 days ago

    Key Takeaways from Hydropothecary’s Fiscal 2Q18 Earnings

    Key Takeaways from Hydropothecary's Fiscal 2Q18 EarningsFiscal 2Q18 earnings

  • March Analyst Ratings and Price Targets for Aphria
    Market Realist29 days ago

    March Analyst Ratings and Price Targets for Aphria

    Aphria (APHQF) was among the worst performers this year with a loss of 34% YTD (year-to-date), which was similar to companies (HMMJ) such as MedReleaf (MEDFF) and Supreme Cannabis (SPRWF). In March, the stock reached a peak of 14.76 Canadian dollars but closed at its lowest point in March at 13.42 Canadian dollars on March 22, 2018. As of March 22, the consensus analyst mean rating on Aphria was 1.75, which remained unchanged from the previous month.

  • Why GMP Securities Is Bullish on Canopy Growth
    Market Realistlast month

    Why GMP Securities Is Bullish on Canopy Growth

    Last week, GMP Securities analyst Martin Landry maintained a “buy” recommendation on the stock with a price target of 40 Canadian dollars. In our recent series, What Analysts Recommend for Cannabis Stocks in March, we looked at recommendations and price targets of cannabis stocks (HMMJ) such as Canopy Growth (WEED), Aurora Cannabis (ACB), MedReleaf (MEDFF), and Cronos (CRON).

  • March Analyst Ratings and Price Target Update for Aurora Cannabis
    Market Realistlast month

    March Analyst Ratings and Price Target Update for Aurora Cannabis

    Aurora Cannabis (ACB) (ACBFF) was one of the biggest losers this year with a YTD (year-to-date) decline of 19%. In March, the stock soared as high as 11.7 Canadian dollars and closed at its lowest point in March at 9.63 Canadian dollars on March 22. Let’s look at how analysts’ ratings and price target has changed over the last month for this company.

  • How Analysts View Canopy Growth
    Market Realistlast month

    How Analysts View Canopy Growth

    Canopy Growth (WEED) is expected to have the highest cannabis growing capacity (HMMJ) compared to Aurora Cannabis (ACB), MedReleaf (MEDFF), and Cronos (CRON). As of March 22, the consensus analyst mean rating on Canopy Growth was 2.6, which remained unchanged from the previous month. While the analyst ratings on Canopy Growth remained unchanged month-over-month in March, the consensus mean price target moved higher to 33.6 Canadian dollars from 33.1, while the median price target remained unchanged at 35 Canadian dollars.

  • CNW Grouplast month

    Horizons Announces March 2018 Distributions for Certain ETFs

    Horizons Announces March 2018 Distributions for Certain ETFs

  • Digging into Aphria’s Cost of Production
    Market Realistlast month

    Digging into Aphria’s Cost of Production

    In this part of the series, we’ll discuss how Aphria’s (APHQF) production costs have evolved in the last four quarters, just as we did for MedReleaf (MEDFF), Aurora Cannabis (ACB), and Canopy Growth (WEED) earlier. In the chart above, we can see that though Aphria’s costs per gram have seen a falling trend sequentially, its fiscal 2Q18, which ended in November 2017, saw a spike. Its cost per gram in this quarter rose to 2.13 Canadian dollars from 1.61 Canadian dollars a quarter ago.

  • How MedReleaf’s Selling Prices Have Evolved in Recent Years
    Market Realistlast month

    How MedReleaf’s Selling Prices Have Evolved in Recent Years

    MedReleaf’s (MEDFF) selling price has seen its ups and downs over the last five quarters, unlike Aurora Cannabis (ACB) (ACBFF) and Canopy Growth (WEED), which have seen upward trends quarter-over-quarter. During its fiscal 3Q18, which ended in December 2017, MedReleaf’s average selling price per gram stood at 8.98 Canadian dollars. Compared to a year earlier, its prices fell as much as 14%.

  • Your Cannabis Sector Update for the Week Ended March 16
    Market Realistlast month

    Your Cannabis Sector Update for the Week Ended March 16

    Your Cannabis Sector Update for the Week Ended March 16Sector ETFs

  • How Aurora Cannabis’s Production Costs Have Evolved
    Market Realistlast month

    How Aurora Cannabis’s Production Costs Have Evolved

    The trend reflects what we saw for Canopy Growth (WEED) earlier in this series. The above chart shows the cash cost evolution for Aurora Cannabis’s dried cannabis sold on a per-gram basis. In its fiscal 2Q18, which ended in December 2017, the company’s cash cost of sales per gram stood at 1.74 Canadian dollars.

  • Forbeslast month

    Avoid Most Cannabis Investment Funds For Now

    Cannabis investing has evolved, with investors now having options to invest in ETFs, mutual funds and other structures. In this article, I review the current landscape, which, unfortunately, doesn't offer a lot of great choices.

  • Comparing Major Cannabis Players’ Prices and Cost Structures
    Market Realistlast month

    Comparing Major Cannabis Players’ Prices and Cost Structures

    Selling prices and per-gram production costs for cannabis will likely be defining factors in the success of Canadian cannabis producers (HMMJ). Most producers will be dealing with one purchaser in each province—the government—which will mean less bargaining power for producers. Pricing in each province will vary depending on demand and the objectives the provincial governments aim to achieve.

  • How Cronos Group Is Expanding Its Cannabis Capacity
    Market Realistlast month

    How Cronos Group Is Expanding Its Cannabis Capacity

    How Cannabis Companies Are Rushing to Expand Operations

  • How MedReleaf’s Capacity Expansion Plans Compare to Its Peers’
    Market Realistlast month

    How MedReleaf’s Capacity Expansion Plans Compare to Its Peers’

    MedReleaf currently has a completed facility of 55,000 square feet in Markham, Ontario. As of the date of this writing, Phase 1 of the Bradford facility is complete, and together with the Markham facility, it has a cultivation capacity of 17,000 kilograms per year.

  • Why Alcaliber Makes Sense for Canopy Growth
    Market Realistlast month

    Why Alcaliber Makes Sense for Canopy Growth

    In the earlier part of the series, we discussed how Aurora Cannabis (ACB) (ACBFF) plans to fund its production facility in Denmark. Aurora Cannabis is not the only Canadian cannabis-licensed producer to eye international markets. On March 6, Bloomberg Markets reported that Canopy Growth (WEED) put in a bid for privately held Spanish company Alcaliber.